ABSTRACT

Objective: The objective of the current study was to evaluate the quality control parameters of seven brands of levofloxacin 500 mg film-coated tablet available in the Yemeni market.

Methods: Physicochemical parameters assay was performed for seven brands of levofloxacin 500 mg film-coated tablet. Each brand was subjected to official and unofficial in vitro quality control tests, including weight variation, thickness, hardness, friability, disintegration, dissolution, and content uniformity assay by High-Performance Liquid Chromatography (HPLC).

Results: Out of seven, six brands of levofloxacin 500 mg film-coated tablet passed official specified assay tests according to the United States Pharmacopeia (USP) specifications. They showed a similar profile of thickness ranged between ±0.01 and 0.10%, friability ranged between 0.01% and 0.34%, disintegration time ranged between 3.00 and 15.00 min, dissolution percentage ranged between 90.65 and 103.05 and content uniformity ranged between 93.62 and 107.12%. Regarding weight variation and hardness, six brands passed the weight variation test and only three brands showed optimum range (10-20 kg) of hardness test. Only one brand failed to pass the weight variation test, and four brands failed to pass the optimum range (10-20 kg) of hardness.

Conclusion: There are no remarkable differences between the seven brands regarding in vitro quality control tests of content uniformity, thickness, friability, disintegration, and dissolution. Even though four brands were above the optimum range of hardiness, they showed complete disintegration and dissolution within the acceptable limit. Regular assessment of marketed drugs is required to ensure bioequivalent to their innovators.

Keywords: Levofloxacin, Quality control, Comparative study, Yemeni market
vitro for comparison between seven commercial brands of levofloxacin 500 mg film-coated tablet available in the Yemeni market.

Samples collection

Seven brands of levofloxacin 500 mg film-coated tablet were obtained from different retail pharmacies in Sana’a, Yemen. Study samples were collected from January 20th to February 20th, 2020. All of the selected brands of levofloxacin were plain compressed uncoated tablets. The seven brands were checked for their strength, batch number, manufacturing and expiry dates, as well as they, were coded from A to G (table 1). All chemicals used were of Analytical Grade, and the standard procedures were used during all analytical processes. The study samples were stored at 25 °C according to the manufacturers’ instructions before evaluation.

Table 1: List of the tested commercial levofloxacin 500 mg film-coated tablet in Yemen

| Country | Code | Brands | Strength | Manufacturer                      | Batch No. | Exp. Date | Mfg. Date | Batch No. |
|---------|------|--------|----------|-----------------------------------|-----------|-----------|-----------|-----------|
| Argentina | A    | Leflumax | 500 mg   | Elea S. K. C. I. F.               | 5466      | 07/2018   | 07/2021   | 07/2018   |
| Egypt   | B    | Lee-flox | 500 mg   | Pharco-Pharma                     | 114705    | 05/2017   | 05/2020   | 05/2017   |
| Yemen   | C    | Levota  | 500 mg   | RFA-Pharma                        | 17A275B   | 12/2017   | 12/2020   | 12/2017   |
| Yemen   | D    | Lefoxin | 500 mg   | Modern Pharma                     | 19138     | 02/2019   | 02/2022   | 02/2019   |
| Yemen   | E    | Levomax | 500 mg   | Y. E. Pharma                      | 5466      | 02/2019   | 02/2022   | 02/2019   |
| India   | F    | Levofab | 500 mg   | Laborate Pharmaceutical            | LINT-002  | 06/2018   | 05/2021   | 05/2021   |
| India   | G    | Levobact | 500 mg   | Cipla ltd.                        | BA80151   | 12/2017   | 11/2020   | 11/2020   |

Physiochemical parameters measurement

Thickness test

Thickness measuring test is necessary to facilitate packaging. To carry out this test, ten tablets from each brand were examined. The mean of each brand was determined in mm within an acceptable variation of±5% of the size of the tablet [9].

Hardness test

The hardness of tablets is essential to withstand mechanical shocks during the different processes of manufacturing, handling, packaging and transporting. Ten tablets were selected from each brand and subjected to Tablet Hardness Tester. Hardness and mean hardness were calculated for each brand. The minimum adequate value of tablet hardness (crushing strength) is 4 kg or above, while the optimum hardness for coated tablets is 10-20 kg [10, 11].

Friability test

Tablet friability is an essential factor for the tablet to withstand attrition in the package container because of shipping and powdering or fragmentation of the tablets during handling and shipping. It can adversely affect the tablet appearance, acceptance, weight variation and content uniformity [12]. Friability test evaluates the impact of transporting tablets from the manufacturer to the point of sale, as no sample is assumed to lose more than 1% of its weight after testing to withstand rough handling and transportation through potholed roads [13]. In order to carry out this process, twenty tablets of each levofloxacin 500 mg brand were weighed initially and then subjected to abrasion using a Friabilator. The Friabilator was set to make 100 revolutions in 4 min. Later on, the tablets were removed from the Friabilator and reweighed again after dusting. The friability was calculated by measuring the difference in weight according to the following equation [14]:

\[
\text{Friability} = \frac{\text{Weight before} - \text{Weight after}}{\text{Weight before}} \times 100
\]

The acceptable limit of friability is up to 1% [15].

Weight variation test

This test is used to ensure a constant dose of drugs between different brands. Twenty tablets were selected from each brand and weighed using an Electronic balance, then each tablet was weighed individually. The average of weight variations for all brands was calculated.

The weight variation for an individual brand should not exceed±5% according to the United State Pharmacopeia (USP) and British Pharmacopeia (BP) standards; to pass, no more than 2/20 tablet differ by more than the percentage permitted and no one tablet differ by more than double the percentage [11, 16, 17].

Disintegration

To measure the time required for tablets to breakdown into small particles, the disintegration test was performed by disintegration tester in a medium of 0.1 N HCL and a temperature of 37±1 °C. A disintegration test is carried out using 6 coated tablets according to the USP. The required time for each tablet to disintegrate and pass out through the mesh was recorded, and the mean disintegration time for each brand was then calculated [18].

Dissolution

The pattern of levofloxacin released over a certain period of time can be determined by the dissolution test. As part of the In vitro-in vivo correlation, all dissolution test parameters should be set to be identical to the human body's conditions [19]. Using the dissolution apparatus, the dissolution medium was prepared with 900 ml of 0.1 N HCL, and the dissolution process was performed at a temperature of 37±0.5 °C and a speed of 75 rpm. Furthermore, an amount of 5 ml as samples were withdrawn every 10 min and replaced with an equal amount of fresh dissolution medium. The obtained samples were subjected to suitably diluted and analyzed for levofloxacin using HPLC at 294 nm, where the absorbance was measured and the percentage of drug release was determined [14, 20].

Content uniformity assay

The active ingredient uniformity test of the tablets was carried out using HPLC. Dihuient and Trifluoroacetic acid were prepared freshly in a ratio of 1000 to 1 were used as the mobile phase; the diluent contains water and acetonitrile in a ratio of 92 to 18. The flow rate of the mobile phase was 0.7 ml/min, and the injection volume of the sample was 20 μL. Levofloxacin detection wavelength was set at 294 nm. The acceptable limit for drug content, chemical compliance and content of active ingredients uniformity tests were carried out in accordance with the standard method specified in USP [17].

Data analysis

Tablets’ weight variation, content uniformity, hardness, friability, thickness, disintegration, and dissolution tests were analyzed by calculating the mean±standard deviation (SD) for each test using IBM SPSS Statistics version 21.0 for Windows (IBM Corp., Armonk, NY, USA).

RESULTS

Thickness, friability, and hardness of levofloxacin brands

Thickness, friability, and hardness results among all brands are summarized in table 2. Among all brands, the average thickness of the seven brands was ranged between±0.01 and 0.10%. Out of seven, four brands failed to pass the optimum range of hardness. The friability test among all brands was ranged from 0.01% to 0.34%; the highest value was found with brand E. The maximum crushing strength was found in brand C (25.76 kg/cm²), while the lowest one was found in brand A (17.33 kg/cm²).
Table 2: Thickness, friability, and hardness for seven brands of levofloxacin 500 mg film-coated tablets

| Code | Thickness (kg/cm²) (n = 10) | Friability (w/w) (n = 20) | Thickness (mm) (n = 10) |
|------|-----------------------------|---------------------------|-------------------------|
| A    | 17.33±0.6                  | 0.01±0.02                 | 5.39±0.01               |
| B    | 25.34±1.7                  | 0.29±0.01                 | 5.55±4±01               |
| C    | 25.76±4.92                 | 0.04±0.04                 | 5.86±10±03              |
| D    | 18.50±1.0                  | 0.04±0.04                 | 5.23±7±10               |
| E    | 21.72±1.0                  | 0.34±0.02                 | 5.45±9±04               |
| F    | 19.98±3.32                 | 0.09±0.06                 | 5.50±10±01              |
| G    | 21.97±1.0                  | 0.01±0.06                 | 5.25±8±04               |
| Limits | 10-20 kg/cm²               | >1%                       | ±5%                     |

Data given in each reading as mean±SD (SD: Standard Deviation)

Official quality control parameters results

Weight variation, disintegration time, dissolution time, and content uniformity of levofloxacin brands results are summarized in Table 3. Mean weight of the seven brands was ranged between 623.1±10.8 for brand E and 968.8±27.7 for brand F, and the weight range for all seven brands was 69%-73% of the mean weight, whereas it was 70%-73% of the mean weight, whereas it was 70-80% for brand C. Mean disintegration time for all brands was ranged between 3.00 to 15.00 min. The mean dissolution time percentage was ranged from 90.650 to 103.05, while the content uniformity for all brands was ranged from 93.62 for brand C to 107.12% for brand E. All brands were compliant with quality control parameters according to USP specification except weight variation, where one brand did not pass the weight variation test.

Table 3: Official quality control parameters for seven brands of levofloxacin 500 mg film-coated tablets

| Code | Weight variation (mg (n = 20) (range % from mean) | Content uniformity (% (n = 20) | Disintegration time (min) (n = 6) | Dissolution time % (after 30 min) (n = 6) |
|------|--------------------------------------------------|-------------------------------|----------------------------------|----------------------------------------|
| A    | 62.5±22                                           | 100.48±540                    | 11.00±0.018                      | 100.71±2.22                           |
| B    | 65.0±51                                           | 99.51±0.267                   | 6.00±0.026                      | 90.65±1.72                            |
| C    | 75.3±25.5                                         | 93.62±0.663                   | 15.00±0.087                     | 99.64±0.65                            |
| D    | 72.3±58                                           | 99.9±0.461                    | 3.00±0.025                      | 100.49±2.70                           |
| E    | 62.1±10.8                                         | 107.12±141                    | 8.00±0.076                      | 100.62±1.19                           |
| F    | 96.8±27.7                                         | 105.0±0.700                   | 12.00±0.028                     | 103.05±0.53                           |
| G    | 657.0±40                                          | 105.0±0.649                   | 7.00±0.021                      | 100.86±1.51                           |
| Limits | ±5                                               | 90-110%                       | 50                              | >80%                                   |

Data given in each reading as mean±SD (SD: Standard Deviation)

DISCUSSION

To the best of our knowledge, this study was conducted as the first one to evaluate official and unofficial quality control parameters of different brands of levofloxacin 500 mg film-coated tablets that were available on the Yemeni market.

The uniformity in the thickness of tablets was pivotal for tablets’ packaging and consumers’ requirements [21]. Our findings showed that the variation of tablets’ thickness was within the accepted limit; ±5%, where it was ranged between±0.01 and 0.10%. In agreement with our findings, a previous study revealed the closeness of all film-coated tablets’ thickness, where the standard deviation was found between 0.02±0.06 [22].

According to USP, the satisfactory limit of friability is not greater than 1% [17]. Our findings of all levofloxacin brands were in agreement with the USP standards and fulfill this criterion to confirm the mechanical stability of all brands. Additionally, this finding was in agreement with previous studies conducted on different brands of levofloxacin 250 mg and ciprofloxacin 500 mg, where they revealed that tablets with the highest value of hardness showed a low friability value [2, 7].

Regarding weight variation, when the strength of the active ingredient is greater than 324 mg in a tablet, its weight variation fulfills the requirements if the mean weight of each brand does not deviate by more than±5% as recommended by USP [17]. The finding of the current study showed that out of seven, six brands (A, B, D, E, F and G) were passed the USP specifications, while brand C did not comply with the USP specifications. The most logical explanation for the discrepancy in the average weight between different products might be attributed to the differences in the excipients and technique during manufacturing. Additionally, the variations of weight might be attributed to the improper tooling sets and poor granulation flow properties during formulation. The variation in the tablet’s weight might cause variances in the tablet’s size that play an important role in the compliance of patients. A comparable study conducted in Pakistan showed remarkable variations in the weight of levofloxacin tablets 250 mg; however, such variations are meaningless as long as the tablet thickness is adjusted accordingly [1].

Additionally, other previous studies revealed that weight variation of the tablet dosage form is also being indicative of the uniformity of drug content, as any weight variation obviously reflects variation in the content of active pharmaceutical ingredients [23-25]. In our study, all the seven brands of levofloxacin, even brand C that did not pass the weight uniformity test, were displayed an acceptable range of drug contents as specified by USP; between 90% and 110% [17]. The slight differences in drug contents among levofloxacin brands may be attributed, in part, to the non-uniform weight of active ingredients or poor storage conditions during the manufacturing process and shipping.

Tablet hardness depends on the weight of the used materials, the nature and quantity of additives or binders used during formulation, and the force of the applied pressure during compression. It, in turn, influences friability, disintegration time, and drug dissolution, which may affect drug bioavailability. Hard tablet hinder the disintegration process, while the soft tablet cannot resist handing during packing and shipping. In the current study, Out of seven, four brands failed to pass the optimum range of hardness; however, their disintegration and dissolution, as well as friability, did not affect accordingly. The reasons behind such a high hardness value might be attributed to the nature, quantity, and the force of compression that was utilized during the manufacturing process [26]. As a result, the high value in hardness making the products able to withstand mechanical shocks during manufacturing, handling, packaging, and transportation processes. This finding was in line with a previous study conducted on metformin tablets, which concluded that the crushing strength of the products was above the satisfactory limit; however, they showed no impact on disintegration [22].
review article emphasized that if the tablet's hardness is too high, it is essential firstly to check its disintegration before rejection. It stated that as long as the disintegration is within acceptable limits, the drug will be accepted and approved [27].

Besides, disintegration refers to the breakup of a tablet into smaller granules, which is an essential process for dissolution and absorption as well as efficacy [28]. According to USP, the disintegration time limit is not to be more than 30 min for uncoated and film-coated tablets. In the present study, all seven brands passed the USP-specific criteria. The discrepancies in the rate of disintegration of all brands might attribute, in part, to the excipients, the physicochemical properties of the active ingredients, the manufacturing procedure, and the amount used of disintegrant [6].

Regarding the dissolution rate, it is required as a pivotal criterion for drug bioavailability to confirm the drug release pattern of the dosage form [19]. All brands in the current study released their active contents in a range of 90.65% to 103.05% within the allowed time as specified by USP.

Compared to the general findings of this study, previous studies performed on levofloxacin 250 mg in Pakistan and India confirmed that all the brands of levofloxacin 250 mg showed satisfactory results regarding the physicochemical parameters tested as the USP specifications [1, 2]. Moreover, another comparable study conducted in Nigeria showed that 60% of the levofloxacin 500 mg tablet brands failed at least in one of the quality control parameters tests, whereas only 40% of the brands passed both physicochemical and bioequivalence tests, and they were interchangeable [29].

CONCLUSION

The findings of this study are clearly demonstrated that all seven brands of levofloxacin 500 mg film-coated tablet, whether manufactured locally or in other countries, exhibited similar profiles to each other in terms of drug content uniformity, disintegration, dissolution, friability, and thickness tests, as well as uniformity test of weight variation for sex brands. Although four studied brands were above the optimum range of hardness, they showed complete disintegration and dissolution within the acceptable limit of USP standards. Particularly, these findings probably help to reinforce the feeling of shared trust between physicians and patients about locally and internationally manufactured medicines. Regular assessment of marketed drugs is required to ensure bioequivalence to their innovators.

ACKNOWLEDGMENT

The authors acknowledge the 5th-year pharmacy students at the University of Science and Technology, 2020-2021, Sana’a, as well as the Modern Pharma Company for the pharmaceutical industry, Yemen for their help during the performance of the study.  

FUNDING

Nil

AUTHORS CONTRIBUTIONS

All the authors have contributed equally.

CONFLICT OF INTERESTS

The authors declare that they have no competing interests.

REFERENCES

1. Bano R, Gauhar S, Naqvi SBS, Mahmood S. Pharmaceutical evaluation of different brands of levofloxacin tablets (250 mg) available in local market of Karach (Pakistan). Int J Curr Pharm Res 2011;3:15-22.
2. Poornachandra TM, Prudviraj A, Robinah K, Roy A, Sivasubramanian L. Comparative in vitro bioavailability studies on different brands of levofloxacin tablets. Acta Sci Pharm Sci 2019;3:50-4.
3. Kumar TM, Srikanth G, Rao JV, Rao K. Development and validation of HPLC-UV method for the estimation of levofloxacin in human plasma Int J Pharm Pharm Sci 2011;3:247-50.
4. Katkam L. Split-half tablets: a complete review for analytical testing. Asian J Pharm Clin Res 2019;12:27-38.
5. Dressman JB, Amidon GL, Reppas C, Shah VP. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res 1998;15:11-22.
6. Alsafi A. Comparative evaluation quality of different brands of ibuprofen 400 mg tablets available in yemen’s market. Chronicle Pharm Sci 2018;2:724-36.
7. Aiyahawi A, Abdulmajeed A. Quality control assessment of different brands of levofloxacin 500 mg tablets in yemen Univ Pharm Res 2018;5:31-6.
8. Al-kershi FA, Othman GQ, Al-qadiasi FA. Quality and stability of amoxicillin-potassium clavulnate drugs marketed in yemen: Influence of tropical storage conditions. J Chem Pharm Res 2016;8:160-16.
9. Chavan H, Chhabra G, Gujarath N, Jadhav A. Comparative study of in-process and finished products quality control test for tablet and capsules according to pharmacopoeia. Asian J Pharm Res Dev 2018;6:60-8.
10. Deshpande RD, Gowda D, Mohammed N, Maramwar DN. Bilayer tablets—an emerging trend: a review. Int J Pharm Sci Res 2011;2:25-34.
11. Hammami MM, Hussein RF, Alsawyeh R, Alvi SN. Eight enteric-coated 50 mg diclofenac sodium tablet formulations marketed in saudi arabia: in vitro quality evaluation. BMC Res Notes 2020;13:1-6.
12. Amin M, Rahman M. Study and impact evaluation of particle size distribution on physicochemical properties of three different tablet formulations through sieve technology. Int J Pharm Res Scholars 2014;3:48-63.
13. Guetchueng ST, Nnanga E. Quality control evaluation of brands of mebendazole 100 mg tablets on the illegitimate pharmacy. Int J Pharm Pharm Res Dev 2018;6:355-7.
14. Kakukuntu R, Veerlapati U, Chepuri M, Raparla R. Effect of various super disintegrants on hardness, disintegration and dissolution of drug from the dosage form. J Adv Sci Res 2010;1:15-9.
15. Lachman L, Lieberman A. The theory and practice of industrial pharmacy. Indian ed. New Delhi: CBS Publication and Distributors; 2009. p. 67-8.
16. Commission BP, Council GM, Commission GBM. British Pharmacopoeia. London: Her Majesty’s Stationery Office; 2013.
17. United States Pharmacopeia and National Formulary USP 39-NF 34; The United States Pharmacopoeial Convention, Inc: Rockville MD; 2016.
18. Gangwar S, Singh S, GardFG, Garg V, Sharma P. To compare the disintegrating property of papa ya starch and sago starch in paracetamol tablets. Int J Pharm Pharm Sci 2016;2 Suppl 2:148-51.
19. Ali BA, Al-haddad MG, Aregi AA. Comparative evaluation of some commercial clopidogrel tablets available in yemen. Majalah Farmaseutik 2017;13:79.
20. Logoyda L, Kovalenko S, Abdel Megid AM, Zhulkeychv I, Drapak I, Demchuk I, et al. Hplc method development for the analysis of bisoprolol in a combined dosage form containing bisoprolol and enalapril and in vitro dissolution studied. Int J Appl Pharm 2019;11:186-94.
21. Nigatu M, Mohammed F, Temesgen A. In vitro comparative study of different brands of pantoprazole sodium enteric-coated tablets marketed in addis ababa, ethiopia. Asian J Pharm Res Dev 2019;7:1-9.
22. Abatea K, Temesgen A, Nigatu M. Comparative in vitro evaluation of different brands of metformin hydrochloride film coated tablets marketed in addis ababa, ethiopia. Asian J Pharm Res Dev 2020;8:44-50.
23. Jakaria M, Moua A, Perez M, Zaman R, Sayeed M, Ali M. In vitro comparative study of different brands of dexamethasone tablet available in bangladesh. Int J Pharm Qual Assur 2020;7:24-8.
24. Sultana S, Hosen MS. In vitro comparative quality evaluation of different brands of esomprazole tablets available in selected community pharmacies in dhaka, bangladesh. BMC Res Notes 2018;11:184.
25. Desta HK, Teklehaimanot TT. *In vitro* quality evaluation of generic ciprofloxacin tablets available in community pharmacies of dessie town, northeast ethiopia. J Generic Med 2020;1:1-8.

26. Kumar P, Ganure AL, Subudhi BB, Shukla S, Upadhayay P. Design and comparative *in vitro* and *in vivo* evaluation of starch-acrylate graft copolymer-based salbutamol sulphate sustained release tablets. Asian J Pharm Sci 2015;10:239-46.

27. Kumar D, Singh J, Antil M, Kumar V. Quality control of tablets: a review. Int J Univers Pharm Bio Sci 2016;5:53-167.

28. Giri TK. Comparative *in vitro* evaluation of conventional ibuprofen marketed formulation. J Pharm Sci Technol 2013;2:75-80.

29. Azubuike CP, Olayase S. Physicochemical and bioequivalence studies on some brands of levofloxacin tablets registered in nigeria. Br J Pharm Res 2014;4:1976-87.